B. Metzler Seel. Sohn & Co. Holding Ag Acadia Pharmaceuticals Inc Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 31,405 shares of ACAD stock, worth $539,223. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,405Holding current value
$539,223% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
279Shares Held
156MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$736 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$238 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$235 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$207 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$103 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.78B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...